Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

2728 results

Sort By:

Boosting Olfactory and Sensory Training Study (BOOST)

Study ID: NCT07221123
Start Date: 2026-01-01
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

80

Intervention / Treatment

Standard Smell Training Group

Overnight Diffuser Grou

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Study ID: NCT07224490
Start Date: 2025-12
End Date: 2030-05
Study Type

Interventional

Study Phase

Phase1

No. of Participants

40

Intervention / Treatment

Kisspeptin 112-121

Sponsor

Stephanie B. Seminara, MD

Source: clinicaltrials.gov

Share:
Add to list

PUQS Sampling Study

Study ID: NCT07199517
Start Date: 2025-12
End Date: 2030-07
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

472

Intervention / Treatment

HRP Sampling period

NPL Sampling period

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

Studying the Effects of Nicotine Concentration and Flavor on Alcohol Use in Young Adults

Study ID: NCT07095140
Start Date: 2026-01-15
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Ecological Momentary Assessment

Monitoring

Nicotine Oral Pouch

Survey Administration

Sponsor

Ohio State University Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach

Study ID: NCT07152184
Start Date: 2026-01-01
End Date: 2032-02-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

288

Intervention / Treatment

Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup

Sponsor

University Hospital, Strasbourg, France

Source: clinicaltrials.gov

Share:
Add to list

Transfusion Exchanges and Cognition in Sickle Cell Disease

Study ID: NCT07168447
Start Date: 2025-12-03
End Date: 2027-11-02
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

85

Intervention / Treatment
Sponsor

St Anne Hospital Center

Source: clinicaltrials.gov

Share:
Add to list

Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test

Study ID: NCT06943768
Start Date: 2025-12-01
End Date: 2026-06-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

9654

Intervention / Treatment

fecal methylation site-based testing and fecal Helicobacter pylori gastric cancer susceptibility gene-based testing

Sponsor

Fudan University

Source: clinicaltrials.gov

Share:
Add to list

Antibiotics for Kidney Transplant Recipients

Study ID: NCT07106125
Start Date: 2026-11
End Date: 2029-01
Study Type

Interventional

Study Phase

Phase4

No. of Participants

50

Intervention / Treatment

Trimethoprim-Sulfamethoxazole (TMP-SMX)

Usual Care

Sponsor

University of California, San Francisco

Source: clinicaltrials.gov

Share:
Add to list

Video Inspired Discussions About Ethical Outcomes in Pediatrics

Study ID: NCT06786104
Start Date: 2026-01-15
End Date: 2030-04-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

567

Intervention / Treatment

VIDEO-PEDS

VIDEO-PEDS pilot

Focus Group

Sponsor

Massachusetts General Hospital

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Study ID: NCT07221149
Start Date: 2026-03-09
End Date: 2032-09-11
Study Type

Interventional

Study Phase

Phase3

No. of Participants

690

Intervention / Treatment

Cool down

Folfox

Capox

Nivolumab

Sponsor

Bristol-Myers Squibb

Source: clinicaltrials.gov

Share:
Add to list